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Lysophosphatidic Acid (LPA) is one of the simplest natural phospholipids. This 
phospholipid is recognized as an extracellular potent lipid mediator with diverse 
effects on various cells. Although LPA is shown to stimulate proliferation and 
motility via LPA receptors, LPA1 and LPA2, in several cancer cell lines, the role 
of LPA and LPA receptors for malignant pleural mesothelioma (MPM) was 
unknown. MPM is an aggressive malignancy with a poor prognosis and the 
incidence is increasing and is expected to more increase for another 10 to 20 
years in worldwide. Therefore development of novel effective therapies needs 
urgently. In this study, we investigated the effect of LPA on the proliferation and
motility of MPM cells. We found that all twelve cell lines and four clinical samples 
of MPM expressed LPA1, and some of them expressed LPA2, LPA3, LPA4, and 
LPA5. LPA stimulated the proliferation and motility of MPM cells in a 
dose-dependent manner. Moreover, LPA-induced proliferation was inhibited by 
Ki16425, an inhibitor of LPA1, and small interfering RNA against LPA1, but not 
LPA2. Interestingly, LPA-induced motility was inhibited by small interfering RNA 
against LPA2, but not LPA1, unlike a number of previous reports. These results 
indicate that LPA is a critical factor on proliferation though LPA1, and on motility 
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though LPA2 in MPM cells. Therefore, LPA and LPA receptors, LPA2 as well as 
LPA1, represent potential therapeutic targets for patients with MPM.
Abbreviations
MPM, malignant pleural mesothelioma; SV40, the simian virus 40; LPA, 
Lysophosphatidic acid; GPCRs, GTP binding protein-coupled receptors; FBS, 
fetal bovine serum; RT-PCR, reverse transcription-PCR; BSA, bovine serum 
albumin; MAPK, mitogen activated protein kinase; SCID, severe combined 
immunodeficiency
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Malignant pleural mesothelioma (MPM) is an aggressive tumor arising from the 
mesothelial cells in the pleural cavity. It is frequently diagnosed at locally 
advanced stage and is refractory to conventional treatment regimens, such as 
chemotherapy and radiation therapy, and so its prognosis is extremely poor. 
Several etiological factors, including asbestos (1,2), iron (3), the simian virus 40
(SV40), radiation and thorotrast (4), have been reported to be involved in the 
development of MPM. Of these factors, exposure to asbestos is most closely 
related to the development of MPM. Prior to the recognition of its adverse health 
effects, large amounts of asbestos were used worldwide. As the latent period 
between the first exposure to asbestos and the occurrence of MPM tends to be 
from 30 to 40 years, it is expected that there will be rapid increases in the 
number of MPM patients in Europe and Australia from 2015 to 2020 (5) and in 
Japan from 2010 to 2040 (2). Thus, the incidence of MPM is expected to
increase further for another 10 to 20 years worldwide, although the disease has 
already reached its peak incidence in the USA (5). The major reasons for the 
poor prognosis of MPM are 1) the highly proliferating and invasive 
characteristics of the disease and 2) its resistance to conventional 
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chemotherapy and radiotherapy. Therefore, novel effective therapeutic 
strategies based on the molecular mechanisms of proliferation and 
motility/invasion of MPM are required to improve the prognosis of this disease.
While several growth factors, including platelet-derived growth factor A and B, 
epidermal growth factor, transforming growth factor , and vascular endothelial 
growth factor, were reported to be involved in the progression of MPM (5), the
molecular mechanisms of the proliferation and motility/invasion of MPM are not 
fully understood.
Lysophosphatidic acid (LPA) is one of the simplest natural phospholipids. It is 
present in serum at concentrations of 2–20 µM (6) and is derived from various 
enzymatic mechanisms, such as activated platelets, fibroblasts, adipocytes, and 
ovarian tumors (6–8). Recently, this phospholipid has attracted a great deal of 
attention as a potent lipid mediator responsible for multiple cellular processes 
(9), such as cell proliferation, platelet aggregation, smooth muscle contraction, 
and cytoskeletal reorganization. In fact, extracellular LPA has been shown to be 
associated with various diseases, including atherosclerosis (10) and cancer 
(11–13). LPA exerts its multiple biological functions via three types of G 
protein-coupled receptor (GPCR), LPA1, LPA2, and LPA3. These receptors 
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share 50–54% amino acid homology and transmit their signals via three families 
of heterotrimeric G proteins, Gi, Gq, and G12/13 (14). Furthermore, more recent 
studies have identified orphan GTP binding protein-coupled receptors (GPCRs), 
LPA4 (15) and LPA5 (16).
The mechanisms of action of LPA receptors differ among subtypes, and they 
are expressed at different levels in both normal and malignant tissues. In 
normal tissues, LPA1 is highly expressed in the brain and heart, LPA2 is highly 
expressed in the testis and leukocytes, LPA3 is highly expressed in the kidney 
and prostate (17,18), and LPA4 is expressed highly in the ovary (15). In 
malignant tumors, LPA1 is dominant in brain tumors (19), LPA2 is predominantly
expressed in colon, stomach, thyroid, and breast cancers (20–22), and LPA3 is 
expressed at relatively high levels in ovarian and prostate cancers (19,23). 
Another study showed that the expression pattern of LPA receptors is 
associated with cancer differentiation in gastric cancer cells (24). Moreover, 
LPA1 has recently been reported to control tumor cell proliferation in prostate 
(25) and breast cancer cells (26) and LPA2 was shown to mediate the growth of 
ovarian (27), thyroid (21), and colon cancer cells (28). Interestingly, LPA1 also 
stimulates the motility of various types of cancer, such as pancreas, colon, 
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glioblastoma, and gastric cancer (19,24,28,29). Thus, LPA receptors play 
crucial roles at least in cancer proliferation and motility/invasion. However, the 
roles of LPA receptors and their downstream signaling pathways in MPM are
unknown.
The present study was performed to explore the expression of LPA receptors 
in human MPM cell lines and further elucidate the roles of five LPA receptors in 
the malignant properties of MPM cells in terms of proliferation and motility.
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Cell lines and culture conditions.
In this study, we used twelve human MPM cell lines, EHMES-1, EHMES-10, 
MSTO-211H, Y-MESO-8A, NCl-H28, NCl-H290, NCl-H513, NCl-H2052, 
NCl-H2373, NCI-H2452, ACC-MESO-1, and ACC-MESO-4. EHMES-1 and 
EHMES-10 (30,31) were kindly provided by Dr Hironobu Hamada (Ehime 
University, Matsuyama, Japan). NCI-H290 and NCI-H513 were kindly provided 
by Dr Adi F. Gazdar (University of Texas Southwestern Medical Center, Dallas, 
TX). Y-MESO-8A, ACC-MESO-1, and ACC-MESO-4 (32) were established in 
Aichi Cancer Center Research Institute. MSTO-211H, NCI-H28, NCI-H2052,
NCI-H2373, and NCI-H2452 were purchased from American Type Culture 
Collection (Manassas, VA).
All human tumor cell lines were maintained in RPMI 1640 medium 
supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml), and 
streptomycin (50 µg/ml); this was designated as RPMI 1640 in this study. Cells 
were cultured in a humidified CO2 incubator at 37°C.
Clinical specimens.
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All human MPM samples were obtained from the Department of Internal 
Medicine and Molecular Therapeutics, University of Tokushima Gradate School. 
Written informed consent was obtained from all subjects prior to tissue 
sampling.
Reagents.
1-Oleoyl-LPA (18:1) and Ki16425 were purchased from Sigma-Aldrich Inc. (St. 
Louis, MO).
Expression of LPA1, LPA2, LPA3, LPA4, and LPA5.
LPA1, LPA2, LPA3, LPA4, and LPA5 mRNA expression were determined by 
reverse transcription-PCR (RT-PCR). Total RNA samples were isolated using 
an RNeasy Mini kit and RNase-free DNase kits (Qiagen, Valencia, CA) in 
accordance with the manufacturer’s recommendations. Total RNAs were 
reverse transcribed using an Omniscript RT kit (Qiagen). The primers for LPA1, 
LPA2, LPA3, LPA4, LPA5, and -actin were as follows:
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LPA1: 5’-TGGCTGCCATCTCTACTTCC-3’ and 
5’-AACCAATCCAGGAGTCCAGC-3’, LPA2: 
5’-CATCATGCTTCCCGACAACG-3’ and 5’-GGGCTTACCAAGGATACGCAG-3’,




and -actin: 5’-AAGAGAGGCATCCTCACCCT-3’ and
5’-TACATGGCTGGGGTGTTGAA-3’.
PCR was performed with Ex Taq Hot Start Version (Takara Bio, Shiga, Japan). 
The bands were visualized by ethidium bromide staining. Data shown are 
representative of three independent experiments.
Cell proliferation assay.
Cell proliferation was measured by the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye reduction 
method (33). Briefly, tumor cells seeded in 96-well plates (5×103 per well) were 
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incubated in RPMI 1640 for 24 h. The cells were starved for 24 h by replacing 
the medium with serum-free RPMI 1640 medium containing 0.1% fatty acid-free 
bovine serum albumin (BSA), with or without LPA and/or Ki16425, an inhibitor 
of LPA1 (and LPA3 at higher doses) (34). The cells were cultured for 48 h. Then, 
an aliquot of 50 µL of stock 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide solution (2 mg/mL; Sigma, St. Louis, MO) was added to each plate and 
the cells were incubated for 2 h at 37°C. The media containing 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide solution were 
removed and the dark blue crystals were dissolved by adding 100 µL of DMSO. 
Absorbance was measured with an MTP-120 microplate reader (Corona Electric, 
Ibaraki, Japan) at test and reference wavelengths of 550 and 630 nm,
respectively. Data shown are representative of three independent experiments.
Cell migration assay.
Cell migration was quantified in Falcon Cell Culture Inserts (pore size 8 µm; BD 
Biosciences, San Jose, CA). Cells suspended in serum-free RPMI 1640 
containing 0.1% fatty acid-free BSA, with or without LPA and/or Ki16425, were 
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added to the upper chamber (1×105 cells in 100 µl/well). Serum-free RPMI 1640 
containing 0.1% fatty acid-free BSA, containing human fibronectin (5 µg/ml; BD 
Biosciences) as a chemoattractant was placed in the lower chamber. When the 
cells treated with Ki16425, the cells were preincubated with 10 µM Ki16425 for 
30 min. The cells were allowed to migrate for 3 h at 37°C. Non-migratory cells 
were removed from the top filter surface with a cotton swab. Migrated cells, 
attached to the bottom surface, were fixed with methanol, stained with Giemsa, 
mounted, and then counted. Data shown are representative of three 
independent experiments.
RNA interference.
Three different duplexed StealthTM RNAi (Invitrogen, Carlsbad, CA) against 
LPA1 and LPA2, and Stealth RNAi Negative Control Kit (Invitrogen) were used 
for RNA interference assay. Briefly, aliquots of 1×105 211H, H28, or H2052 cells
in 2 ml of antibiotic-free medium were plated on 6-well plates and incubated at 
37°C for 24 h, and the cells were then transfected with siRNA (250 pmol) or 
scramble RNA (siSCR) using Lipofectamine 2000 (5 µl) in accordance with the 
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manufacturer’s instructions. After 24-h incubation, the cells were washed twice 
with PBS, and incubated in antibiotic-containing medium. These cells were then 
used for proliferation or migration assay as described above. LPA1 and LPA2
knockdown were confirmed by RT-PCR analysis. The sense sequences of 
siRNA were as follows:
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Tumor cells were washed twice with PBS, harvested in cell lysis buffer (20 mM 
Tris, pH7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM 
sodium pyrophosphate, 1 mM -glycerolphosphate, 1 mM Na3VO4, 1 µg/ml 
leupeptin, and 1 mM phenylmethylsulfonyl fluoride), and flash-frozen on dry ice. 
After allowing the cells to thaw, the cell lysates were collected with a rubber 
scraper, sonicated, and centrifuged at 14000×g (4°C for 20 min). The total 
protein concentration was measured using a Pierce BCA Protein Assay Kit 
(Pierce, Rockland, IL). Cell lysates were subjected to SDS-polyacrylamide gel 
electrophoresis, and the proteins were then transferred onto PVDF membranes 
(Atto, Tokyo, Japan). The membranes were blocked with Blocking One (Nacalai 
Tesque Inc, Kyoto, Japan) for 1 h at room temperature, and then the blots were 
incubated at 4°C overnight with anti-phospho-p44/42 mitogen-activated protein 
kinase (MAPK) (Thr202/Tyr204), anti-p44/42 MAPK (1:1000 dilution; Cell 
Signaling Technology, Beverly, MA), or anti--actin antibody (1:5000 dilution; 
Sigma), followed by incubation for 2 h at room temperature with secondary Ab 
(horseradish peroxidase-conjugated species-specific Ab). Immunoreactive 
bands were visualized using enhanced chemiluminescent substrate (Pierce).
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We determined RhoA activation as the amount of RhoA-GTP binding using a
G-LISA RhoATM Activation Assay Biochem KitTM (Cytoskeleton, Denver, CO), in 
accordance with the manufacturer’s recommendations. Briefly, tumor cells 
(2×105 per well) seeded in 6-well plates were incubated in RPMI 1640 containing 
10% FBS for 24 h. The cells were starved for 24 h by replacing the medium with 
serum-free RPMI 1640 medium containing 0.1% BSA. The dishes were then 
treated with LPA (10 µM) for 0, 1, 3, 6, 12, and 30 min. The tumor cells were 
washed twice with PBS and harvested in cell lysate with a cell scraper, 
sonicated, and centrifuged at 10000×g (4°C for 2 min). The total protein 
concentration was measured using Precision RedTM Advanced Protein Assay 
Reagent. Equal amounts of cell lysate protein were incubated in Rho-GTP 
affinity plates for 30 min at 4°C. To the plates was added anti-RhoA primary 
antibody, followed by secondary HRP-labeled antibody and HRP detection 
reagent, and incubated at room temperature for the time recommended by the 
manufacturer. Absorbance was measured with an MTP-120 microplate reader 
at wavelength of 490 nm. Data shown are representative of three independent 
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experiments with similar results.
Statistical analysis.
All data, expressed as means ± SE, were analyzed by one-way analysis of 
variance. The statistical significance of differences was assessed by the Fisher 
protected least-significant difference test. P values less than 0.05 were 
considered statistically significant. Statistical analyses were performed using 
StatView ver.5.0. 
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Human MPM cell lines expressed LPA1, LPA2, LPA3, LPA4, and LPA5 at 
various levels.
In the first set of experiments, we examined the mRNA expression of five LPA 
receptors (LPA1, LPA2, LPA3, LPA4, and LPA5) in twelve human MPM cell lines 
by RT-PCR (Fig. 1A). All of the MPM cell lines examined expressed LPA1
mRNA at various levels. Of these cell lines, 211H, H28, H290, H2052, and 
H2373 cells showed higher levels of expression as compared with the others. 
On the other hand, some of the MPM cell lines expressed LPA2. Y-MESO-8A, 
H290, H2052, and ACC-MESO-4 cells showed high levels of LPA2 expression 
as compared with the other cell lines. Similarly, some of the MPM cell lines 
expressed LPA3, LPA4, and LPA5. In parallel experiments, we examined LPA1, 
LPA2, LPA3, LPA4, and LPA5 mRNA expression in tumor specimens obtained 
from four patients with MPM (Fig. 1B). Consistent with the results in the cell 
lines examined, all samples expressed LPA1 and some expressed LPA2, LPA3, 
LPA4, and LPA5.
LPA stimulated the proliferation of MPM cells via LPA1. 
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We determined the effects of LPA on proliferation of MPM cells. Exogenous 
LPA at physiological concentrations (up to 20 µM) significantly stimulated the 
proliferation of 5 of the 11 MPM cell lines examined (data not shown). Of these
cell lines, 211H and H28 cells responded well to LPA in a dose-dependent
manner (Fig. 2A). Therefore, these two cell lines were used to investigate 
whether LPA receptors are involved in LPA-induced proliferation, when the 
effects of Ki16425, an inhibitor of LPA1 (and LPA3 at higher doses), on 
proliferation were examined. Ki16425 inhibited LPA-induced proliferation of both 
211H and H28 cells in a dose-dependent manner (Fig. 2B). In a parallel 
experiment, we examined the effects of small interfering RNA (siRNA) against 
LPA1 and LPA2. Knockdown of LPA1 resulted in significant inhibition of the 
LPA-induced proliferation of both 211H and H28 cells. These results were 
confirmed using serum-starved media with LPA, as well as media containing 
10% FBS (data not shown). However, knockdown of LPA2 had little impact on 
LPA-induced proliferation of 211H or H28 cells (Fig. 2C). These results 
indicated that LPA stimulated the proliferation of these two MPM cell lines via 
LPA1 receptors.
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LPA activates p44/42 MAPK through LPA1. 
To determine the mechanism by which LPA1-mediated proliferation of MPM 
cells, we next examined the phosphorylation of MAPK, which is the downstream 
signal of GPCRs. MPM cells were stimulated with LPA (10 µM) for 0, 2, or 6 h, 
and the phosphorylation of MAPK was evaluated by Western blotting. While 
LPA did not affect MAPK protein expression, it induced the phosphorylation of 
MAPK (phospho-p44/42 MAPK) in both 211H and H28 cells. The level of 
phosphorylation became highest after 2 h and the effect was still substantial 
after 6 h (Fig. 3A). Therefore, we evaluated the phosphorylation of MAPK after 
2-h incubation with LPA. In a parallel experiment, siRNA knockdown of LPA1, 
but not of LPA2, markedly reduced the phosphorylation of p44/42 MAPK in 
these two MPM cell lines (Fig. 3B), indicating that LPA activates the p44/42 
MAPK pathway via LPA1.
LPA stimulates cell motility via LPA2. 
We next examined the effect of LPA on the motility of MPM cells using a cell 
migration assay. LPA stimulated migration of 6 of 10 MPM cell lines (data not 
shown). Of these MPM cell lines, LPA induced a significant increase in 
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migration of H2052, H2373, and ACC-MESO-4 cells in a dose-dependent 
manner (Fig. 4A). However, it did not affect the proliferation of these MPM cells
(data not shown). These observations exclude the possibility that the effect of 
cell motility was attributable to differences in proliferation. In turn, these cell 
lines were used to examine whether LPA receptors were involved in 
LPA-induced motility, when the effect of Ki16425, an inhibitor of LPA1 (and LPA3
at higher doses), on the motility was examined. Ki16425 had no effect on 
LPA-induced motility in these MPM cells (Fig. 4B). To clarify the involvement of 
LPA1 and LPA2, we further knocked down LPA1 and LPA2 expression, 
respectively, with siRNA using H2052 cells, because LPA induced the motility of 
H2052 cells most efficiently. Knockdown of LPA2 markedly inhibited 
LPA-induced motility of H2052 cells, while knockdown of LPA1 did not (Fig. 4C). 
These results strongly suggest that LPA induces motility via LPA2 in H2052 
cells.
LPA activates RhoA through LPA2. 
We next investigated the effects of LPA on the activation of RhoA, which is a 
downstream signal of GPCRs and one of the key molecules for cell motility. 
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H2052 cells were stimulated with LPA (10 µM) for 0, 1, 3, 6, 12, or 30 min, and 
activation of RhoA was evaluated by G-LISA RhoATM Activation Assay
(Biochem KitTM). LPA induced activation of RhoA, the degree of which became 
strongest after 1 min, and the effect decreased within 30 min (Fig. 5A).
Therefore, we evaluated RhoA after 1-min incubation with LPA. Knockdown of 
LPA2 with siRNA, but not of LPA1, significantly reduced RhoA activation in 
comparison with the control level (Fig. 5B). These results suggest that LPA 
stimulates cell motility through an LPA2-mediated RhoA pathway.
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In the present study, we demonstrated that all of the twelve cell lines and four 
clinical samples of MPM examined expressed LPA1, while other types of LPA 
receptors (LPA2, LPA3, LPA4, and LPA5) were expressed only in some of the 
cell lines and clinical samples, and LPA stimulated the proliferation and motility 
of several MPM cell lines in a dose-dependent manner. There was no apparent
correlation between the response to LPA and the expression level of LPA 
receptors, although MPM cells with high level of LPA1 tend to be stimulated 
proliferation by LPA (data not shown). The histological subtypes, such as 
epithelial, biphasic, and sarcomatoid, were not also particularly correlated with 
the response to LPA (data not shown). We also examined the role of LPA and 
its receptors using a non-cancerous mesothelial cell line, Met-5A. Met-5A cells 
expressed LPA1 and LPA2, and LPA induced the proliferation, but not migration 
(data not shown). These observations suggest that MPM is biologically 
heterogeneous and uses various factors and signaling pathways for cell 
proliferation and motility. Our results also clearly showed that particular 
populations of MPM cells essentially utilized the LPA/LPA receptor pathway for 
both cell proliferation and motility. As the biomarker for MPM, Lindholm et.al 
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reported that gene copy number losses are a major mechanism for 
carcinogenesis and copy number changes are associated with a recurrent 
pattern (35). Pass et al. reported to predict survival and progression of MPM 
patients, using a 27-gene expression profiles (36). However, to our knowledge, 
this is the first report of the involvement of LPA/LPA receptors in the malignant 
phenotype of MPM.
LPA is known to act on specific GPCRs to elicit a wide range of cellular 
responses, ranging from cell proliferation and motility of various types of solid 
tumor (37). MPM tends to advance locally with pleural effusion, rather than 
distant metastasis, and the extent of the disease is directly associated with the 
prognosis of MPM patients (5). It is important to understand the molecular 
mechanism of MPM pathogenesis in terms of proliferation and motility, because 
molecules responsible for MPM progression seem to be ideal targets for
therapy of MPM.
Recently, the differential roles of five GPCRs as LPA receptors have 
attracted a great deal of attention. Of these receptors, LPA1 and LPA2 are 
thought to play important roles in the signaling pathways of cancer cells. 
Several studies indicated that LPA1 controls cell proliferation in prostate cancer 
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(25) and breast cancer cells (26). Similarly, LPA2 was found to mediate
LPA-induced growth of ovarian (27), thyroid (21), and colon cancer cells (29). 
Thus, the role of LPA receptors in cell proliferation triggered by LPA appears to
depend on the type of cancer cell line examined. In this study, we demonstrated 
that LPA1, but not LPA2, is a key receptor in LPA-stimulated proliferation of 
MPM cells using silencing of LPA receptors.
GPCRs, including LPA receptors, have multiple intracellular signaling 
mechanisms by small GTPase proteins, Ras, Rho, Rac, and their downstream 
cascades (37,38). The activation of Ras-MAPK responsible for cell proliferation
can lead to the nuclear translocation of MAPK followed by gene transcription 
and cell cycle progression, and this signaling plays a pivotal role in cancer cell 
proliferation and differentiation. In the present study, we showed that LPA 
activated the p44/42 MAPK pathway and siRNA for LPA1, but not LPA2, caused 
marked inhibition of cell proliferation and phosphorylation of p44/42 MAPK. 
These results strongly suggest that MAPK is involved in the LPA1-mediated 
proliferation of MPM cells induced by LPA.
MPM cells have high motility, facilitate free movement in the pleural cavity 
during respiration by extending lubricating glycoproteins, and show disordered 
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invasion into the thoracic cavity (5). LPA is already well known to stimulate cell 
motility in many cell types, such as fibroblasts, gliomas, and T-cell lymphomas 
(39). LPA-stimulated motility of cancer cells was recently reported to require 
signaling via LPA1 in many types of solid tumor, including pancreas, colon, 
glioblastoma, and gastric cancer (19,24,28,29). However, this was not the case
in our studies that indicated that the motility of MPM cells was augmented by 
LPA through LPA2, but not LPA1. This was confirmed in the present study using 
two different methods. First, treatment with Ki16425, an inhibitor of LPA1, did 
not inhibit cell migration. Second, knockdown of LPA2, but not LPA1, effectively 
suppressed LPA-induced motility of MPM (H2052) cells. These results 
demonstrated that LPA-induced motility of MPM cells is mediated partly, if not 
completely, through its interaction with LPA2.
RhoA is a small GTPase protein that mediates actin microfilament organization 
necessary for adhesion, motility, and changes in cell shape (40). Recent studies 
have implicated the pathway of RhoA activation, which acts downstream of LPA 
receptors, in tumor invasion (41,42). We demonstrated that LPA activated RhoA 
and that the effect was significantly, but not completely, diminished by 
knockdown of LPA2, suggesting that LPA stimulated migration of H2052 cells 
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was mediated by LPA2 through the RhoA activation pathway. Further studies 
are warranted to determine the involvement of other signaling pathways in 
LPA2-mediated cell-motility of MPM cells.
To explore antitumor activity by inhibiting LPA receptors, we used an inhibitor 
of LPA1, Ki16425, because it is only one commercially available LPA inhibitor at 
present. The severe combined immunodeficiency (SCID) mice bearing 
subcutaneously inoculated MSTO-211H cells were treated daily from day 19 to 
day 30 with s.c. injection of Ki16425 at 20 mg/kg per day. The tumor growth 
was measured every 3 days. Under these experimental conditions, treatment 
with Ki16425 did not significantly inhibit the tumor growth of MSTO-211 cells
(data was not shown). However, we can not make conclusion by this 
experiment, because Ki16425 is an inhibitor of LPA1, but not LPA2. In addition, 
since limited amount of Ki16425 was available, only one dose of Ki16425 was 
used and treatment was given only 12 days started at late stage. Therefore, 
further experiments with higher doses of Ki16425 for longer duration or dual 
inhibitors of LPA1 and LPA2, if available, are warranted to elucidate real role of 
LPA receptors in mesothelioma cells in vivo.
In summary, we demonstrated that MPMs are heterogeneous in terms of the 
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response to LPA and the expression of LPA receptors. However, at least in 
particular populations of MPM, LPA stimulated proliferation via LPA1 through 
MAPK and motility via LPA2 through RhoA. These novel findings suggest that 
LPA1 and LPA2 may be one of therapeutic targets for controlling the proliferation 
and motility of MPM cells. As MPM develops into locally advanced disease, 
novel strategies targeting both LPA1 and LPA2 might be beneficial for 
suppressing the progression of MPM. Further in vivo experiments with dual 
inhibitors of LPA1 and LPA2, are warranted.
Page 29 of 47

































































This work was supported by Grants-in-Aid 17016051 for Cancer Research from 
the Ministry of Education, Science, Sports and Culture of Japan (S.Sone). We 
thank Dr Hironobu Hamada for the EHMES-1 and EHMES-10 cell lines and Dr 
Adi F. Gazdar for the NCI-290 and NCI-H513 cell lines.
Page 30 of 47

































































1. Broaddus VC. Asbestos, the mesothelial cell and malignancy: a matter of life 
or death. Am J Respir Cell Mol Biol 1997; 17: 657-9.
2. Morinaga K, Kishimoto T, Sakatani M, Akira M, Yokoyama K, Sera Y. 
Asbestos-related lung cancer and mesothelioma in Japan. Industrial Health 
2001; 39, 65-74.
3. Dufresne A, Bégin R, Churg A, Massé S. Mineral fiber content of lungs in 
patients with mesothelioma seeking compensation in Quebec. Am J Respir 
Crit Care Med 1996; 153: 711-8.
4. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma.
Semin Oncol 2002; 29: 2-17.
5. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J 
Med 2005; 353: 1591-603.
6. Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH. The bioactive 
phospholipid lysophosphatidic acid is released from activated platelets.
Biochem J 1993; 291: 677-80.
Page 31 of 47
































































7. Gerrard JM, Robinson P. Identification of the molecular species of 
lysophosphatidic acid produced when platelets are stimulated by thrombin. 
Biochim Biophys Acta 1989; 1001: 282–5.
8. Shen Z, Belinson J, Morton RE, Xu Y, Xu Y. Phorbol 12-myristate 
13-acetate stimulates lysophosphatidic acid secretion from ovarian and 
cervical cancer cells but not from breast or leukemia cells. Gynecol Oncol
1998; 71: 364–8.
9. Aoki J, Taira A, Takanezawa Y, et al. Serum lysophosphatidic acid is 
produced through diverse phospholipase pathways. J Biol Chem 2002; 277:
48737-44.
10.Siess W, Zangl KJ, Essler M, et al. Lysophosphatidic acid mediates the 
rapid activation of platelets and endothelial cells by mildly oxidized low 
density lipoprotein and accumulates in human atherosclerotic lesions. Proc 
Natl Acad Sci U S A 1999; 96: 6931-6.
11.Fang X, Schummer M, Mao M, et al. Lysophosphatidic acid is a bioactive 
mediator in ovarian cancer. Biochim Biophys Acta 2002; 1582: 257-264.
12.Mills GB, May C, Hill M, Campbell S, Shaw P, Marks A. ascitic fluid from 
human ovarian cancer patients contains growth factors necessary for 
Page 32 of 47
































































intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest
1990; 86: 851-5.
13.Xu Y, Gaudette DC, Boynton JD, et al. Characterization of an ovarian cancer 
activating factor in ascites from ovarian cancer patients. Clin Cancer Res
1995; 1: 1223-1232.
14.Contos JJ, Ishii I, Chun J. Lysophosphatidic acid receptors. Mol Pharmacol
2000; 58: 1188-96.
15.Noguchi K, Ishii S, Shimizu T. Identification of p2y9/GPR23 as a novel G 
protein-coupled receptor for lysophosphatidic acid, structurally distant from 
the Edg family. J Biol Chem 2003; 278: 25600-6.
16.Lee CW, Rivera R, Gardell S, Dubin AE, Chun J. GPR92 as a new G12/13-
and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. 
J Biol Chem 2006; 281: 23589-97.
17.An S, Bleu T, Hallmark OG, Goetzl EJ. Characterization of a novel subtype 
of human G protein-coupled receptor for lysophosphatidic acid. J Biol Chem
1998; 273: 7906-10.
Page 33 of 47
































































18.Bandoh K, Aoki J, Hosono H, et al. Molecular cloning and characterization of 
a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. 
J Biol Chem 1999; 274: 27776-85.
19.Kishi Y, Okudaira S, Tanaka M, et al. Autotaxin is overexpressed in 
glioblastoma multiforme and contributes to cell motility of glioblastoma by 
converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem
2006; 281: 17492-500.
20.Shida D, Watanabe T, Aoki J, et al. Aberrant expression of lysophosphatidic 
acid (LPA) receptors in human colorectal cancer. Lab Investig 2004; 84:
1352-62.
21.Schulte, KM, Beyer A, Köhrer K, Oberhäuser S, Röher HD. 
Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: 
over-expression of the high-affinity receptor edg4 in differentiated thyroid 
cancer. Int J Cancer 2001; 92: 249-56.
22.Kitayama J, Shida D, Sako A, et al. Over-expression of lysophosphatidic 
acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res
2004; 6: R640-R646.
Page 34 of 47
































































23.Mills GB, Eder A, Fang X, et al. Critical role of lysophospholipids in the 
pathophysiology, diagnosis, and management of ovarian cancer. Cancer 
Treat Res 2002; 107: 259-83.
24.Shida D, Kitayama J, Yamaguchi H, et al. Dual mode regulation of migration 
by lysophosphatidic acid in human gastric cancer cells. Exp Cell Res 2004;
301: 168-78.
25.Guo R, Kasbohm EA, Arora P, et al. Expression and function of 
lysophosphatidic acid LPA1 receptor in prostate cancer cells. Endocrinology
2006; 147: 4883-92.
26.Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, Peyruchaud 
O. The type 1 lysophosphatidic acid receptor is a target for therapy in bone 
metastases. Proc Natl Acad Sci U S A 2006; 103: 9643-8.
27.Goetzl EJ, Dolezalova H, Kong Y, et al. Distinctive expression and functions 
of the type 4 endothelial differentiation gene-encoded G protein-coupled 
receptor for lysophosphatidic acid in ovarian cancer. Cancer Res 1999; 59:
5370-5.
Page 35 of 47
































































28.Shida D, Kitayama J, Yamaguchi H, et al. Lysophosphatidic Acid (LPA) 
Enhances the Metastatic Potential of Human Colon Carcinoma DLD1 Cells 
through LPA1. Cancer Res 2003; 63: 1706-11.
29.Yamada T, Sato K, Komachi M, et al. Lysophosphatidic acid (LPA) in 
malignant ascites stimulates motility of human pancreatic cancer cells 
through LPA1. J Biol Chem 2004; 279: 6595-605.
30.Yokoyama A, Kohno N, Fujino S, et al. Origin of heterogeneity of 
interleukin-6 (IL-6) levels in malignant pleural effusions. Oncol Rep 1994; 1: 
507-511.
31.Nakataki E, Yano S, Matsumori Y, et al. Novel orthotopic implantation model 
of human malignant pleural mesothelioma (EHMES-10 cells) highly 
expressing vascular endothelial growth factor and its receptor. Cancer Sci 
2006; 97: 183-91.
32.Usami N, Fukui T, Kondo M, et al. Establishment and characterization of 
four malignant pleural mesothelioma cell lines from Japanese patients. 
Cancer Sci 2006; 97: 387-94.
33.Yano S, Muguruma H, Matsumori Y, et al. Antitumor Vascular Strategy for 
Controlling Experimental Metastatic Spread of Human Small-Cell Lung 
Page 36 of 47
































































Cancer Cells with ZD6474 in Natural Killer Cell–Depleted Severe Combined 
Immunodeficient Mice. Clin Cancer Res 2005; 11: 8789-98.
34.Ohta H, Sato K, Murata N, et al. Ki16425, a subtype-selective antagonist for 
EDG-family lysophosphatidic acid receptors. Mol Pharmacol 2003; 64:
994-1005.
35.Lindholm PM, Salmenkivi K, Vauhkonen H, et al. Gene copy number 
analysis in malignant pleural mesothelioma using oligonucleotide array CGH.
Cytogenet Genome Res 2007; 119: 46-52.
36.Harvey I. Pass, Zhandong Liu, Anil Wali, et al. Gene Expression Profiles 
Predict Survival and Progression of Pleural Mesothelioma. Clin Cancer Res
2004; 10: 849-859.
37.Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in 
cancer. Nat Rev Cancer 2003; 3: 582-91.
38.Stähle M, Veit C, Bachfischer U, et al. Mechanisms in LPA-induced tumor 
cell migration: critical role of phosphorylated ERK. J Cell Sci. 2003; 116:
3835-46.
Page 37 of 47
































































39.Hama K, Aoki J, Fukaya M, et al. Lysophosphatidic acid and autotaxin 
stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J 
Biol Chem 2004; 279: 17634-9.
40.Do TV, Symowicz JC, Berman DM, et al. Lysophosphatidic Acid 
Down-Regulates Stress Fibers and Up-Regulates Pro–Matrix 
Metalloproteinase-2 Activation in Ovarian Cancer Cells. Mol Cancer Res
2007; 5: 121-31.
41.Michiels F, Habets GG, Stam JC, van der Kammen RA, Collard JG. A role 
for Rac in Tiam1-induced membrane ruffling and invasion. Nature 1995;
375: 338-40.
42. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. An 
essential part for Rho-associated kinase in the transcellular invasion of 
tumor cells. Nat Med 1999; 5: 221-5.
Page 38 of 47

































































Figure 1. Expression of LPA receptors, LPA1, LPA2, LPA3, LPA4, and LPA5
in human MPM cell lines, and clinical specimens.
Reverse transcription-PCR was performed to determine expression of the LPA 
receptors, LPA1, LPA2, LPA3, LPA4, and LPA5. Reverse transcription-PCR 
products were electrophoresed on a 2% agarose gel and stained with ethidium 
bromide. Data shown are representative of three independent experiments with 
similar results.
Figure 2. Effects of LPA on cell proliferation of human MPM cells, and 
inhibition by antagonist and knockdown of LPA1. 
Tumor cells (5×103 per well) plated in triplicate in 96-well plates were incubated
overnight in RPMI 1640 containing 10% FBS. The cells were starved for 24 h by 
replacing the media with serum-free RPMI 1640 containing 0.1% fatty acid-free 
bovine serum albumin. Different doses of LPA and Ki16425, an inhibitor of LPA1, 
were then added, and the cells were cultured for 48 h. Then, an aliquot of 50 µL
of stock 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide solution (2 
mg/mL; Sigma, St. Louis, MO) was added to each plate and the cells were 
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incubated for 2 h at 37°C. LPA stimulated proliferation of 211H and H28 cells in 
a dose-dependent manner (A). LPA-induced proliferation of 211H and H28 cells 
was inhibited by Ki16425 in a dose-dependent manner (B). After transfection 
with siRNA or scramble RNA (siSCR) using Lipofectamine 2000 in accordance 
with the manufacturer’s instructions, the cells were starved for 24 h by replacing 
the media with serum-free RPMI 1640 containing 0.1% fatty acid-free BSA. LPA 
(10 µM) was then added and cells were cultured for 48 h. The cells were then 
subjected to 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. 
Knockdown of LPA1 (siLPA1#1, siLPA1#2, and siLPA1#3) significantly inhibited 
LPA-induced proliferation of 211H and H28 cells, while knockdown of LPA2
(siLPA2#1, siLPA2#2, and siLPA2#3) had little impact on LPA-induced 
proliferation of 211H or H28 cells (C). Data shown are representative of three 
independent experiments with similar results. * Significantly different from 
control (P<0.001). ** Significantly different from siSCR (P<0.005).
Figure 3. Effects of LPA on phospho-p44/42 MAPK, and inhibition by 
knockdown of LPA1. 
Tumor cells were incubated with LPA (10 µM) for 0, 2, and 6 h. Then, the cell 
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lysates were harvested and the protein level and phosphorylation of p44/42 
MAPK were determined by immunoblotting analysis. LPA-induced 
phosphorylation in 211H and H28 cells occurred after 2 h, and the effect was 
still substantial after 6 h (A). Moreover, knockdown of LPA1 with siRNA 
markedly reduced the activation of p44/42 MAPK. However, knockdown of LPA2
had little impact (B). Data shown are representative of three independent 
experiments with similar results.
Figure 4. Effects of LPA on migration of human MPM cells, and inhibition 
by knockdown of LPA2. 
Cell migration was measured in Falcon Cell Culture Inserts (pore size 8 µm). 
Cells suspended in serum-free RPMI 1640 containing 0.1% fatty acid-free BSA 
with or without LPA and/or Ki16425 were added to the upper chamber (1×105
cells at 100 µl/well). Serum-free RPMI 1640 containing 0.1% fatty acid-free BSA 
and human fibronectin (5 µg/ml) as a chemoattractant was added to the lower 
chamber. When the cells treated with Ki16425, the cells were preincubated with 
10 µM Ki16425 for 30 min. The cells were allowed to migrate for 3 h at 37°C. 
LPA stimulated migration of MPM cells, H2052, H2373, and ACC-MESO-4 in a 
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dose-dependent manner (A). Ki16425 had no effect on LPA-induced motility in 
these MPM cells (B). After transfection with siRNA or scramble RNA (siSCR), 
the cells were starved for 24 h by replacing the media with serum-free RPMI
1640 containing 0.1% fatty acid-free BSA. Knockdown of LPA2 by siRNA 
significantly inhibited the LPA-induced motility of H2052 cells, while knockdown 
of LPA1 did not (C). Data shown are representative of three independent 
experiments. * Significantly different from control (P<0.005). ** Significantly 
different from siSCR (P<0.005).
Figure 5. Effects of LPA on RhoA activity, and inhibition by knockdown of 
LPA2. 
To assess RhoA activation, we determined RhoA activation as the amount of 
RhoA-GTP binding using a G-LISA RhoATM Activation Assay Biochem KitTM
(Cytoskeleton, Denver, CO) in accordance with the manufacturer’s 
recommendations. H2052 cells were treated with LPA (10 µM) for 0, 1, 3, 6, 12, 
and 30 min, and the cell lysates were then prepared for the assay. LPA 
stimulation of RhoA activity in H2052 cell was highest after 1 min and the effect 
decreased within 30 min (A). Knockdown of LPA2 with siRNA significantly 
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reduced the activation of RhoA, while knockdown of LPA1 had little effect (B). 
Data shown are representative of three independent experiments. * Significantly 
different from control (P<0.05). ** Significantly different from siSCR (P<0.005).
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